Invasive Cervical Cancer Management (Diagnosis Through Definitive Treatment)
Invasive cervical cancer is managed with curative-intent stage-adapted multimodality therapy and with palliative-intent systemic therapy for metastatic or recurrent disease. Curative treatment planning is based on FIGO/TNM stage, pathologic risk factors, and the feasibility of surgical staging or definitive chemoradiation ESMO 2023 Gynaecological Cancers. Treatment selection is guided by ASCO resource-stratified recommendations for invasive cervical cancer ASCO Rapid Recommendation Update (2022).
Diagnostic Workup and Staging Confirmation
Initial evaluation should include cervical exam with biopsy confirmation, pathologic subtype assessment, and imaging for local extent and nodal/distant disease assessment ESMO 2023 Gynaecological Cancers. PET/CT is commonly used for nodal and distant staging when suspicion exists for lymph node involvement or higher-risk locally advanced presentations [1].
Treatment Selection Algorithm by Stage
Early-stage disease (FIGO IA1 to IIA)
Early-stage disease is treated either with fertility-sparing excision or with hysterectomy approaches, with surgical nodal assessment used for staging ESMO 2023 Gynaecological Cancers. Sentinel lymph node mapping is used in selected patients undergoing minimally invasive or surgical approaches when appropriate for risk stratification and to reduce morbidity from full lymphadenectomy [1].
Locally advanced disease (generally FIGO IB3 to IVA)
Locally advanced cervical cancer is treated with definitive concurrent chemoradiation followed by brachytherapy ESMO 2023 Gynaecological Cancers. The definitive regimen uses external-beam radiation with concurrent platinum-based chemotherapy followed by uterovaginal (or intracavitary/interstitial) brachytherapy as local-dose intensification [2].
Metastatic or recurrent disease
Recurrent or metastatic disease is treated with systemic therapy selection based on prior treatment exposure, performance status, and biomarker- and histology-informed options consistent with ASCO recommendations ASCO Rapid Recommendation Update (2022).
Definitive Surgery and Postoperative Adjuvant Therapy
Surgery in early-stage disease should include hysterectomy-based management or conization-based management when oncologically appropriate, with nodal assessment to determine pathologic risk ESMO 2023 Gynaecological Cancers. Postoperative treatment is determined by pathologic risk categories, including high-risk features and intermediate-risk features [3].
Chemoradiation and Brachytherapy Principles in Locally Advanced Disease
Definitive chemoradiation is delivered with concurrent platinum-based chemotherapy given during external-beam radiation ESMO 2023 Gynaecological Cancers. Brachytherapy is used after external-beam radiation to improve local control through higher conformal dose delivery to the cervix/uterus region [3]. In KEYNOTE-A18, chemoradiation consisted of external-beam radiation with brachytherapy and weekly cisplatin chemotherapy for 5–6 cycles, with pembrolizumab vs placebo administered concurrently and continued as monotherapy [2].
Monotherapy Versus Combination Therapy
Postoperative strategies
High-risk postoperative settings support combined-modality treatment with radiation plus systemic therapy (commonly concurrent platinum-based chemotherapy) according to pathologic risk stratification [3].
Locally advanced definitive chemoradiation
Definitive concurrent chemoradiation uses combination therapy (radiation plus chemotherapy) to improve outcomes compared with radiation alone in standard practice ESMO 2023 Gynaecological Cancers.
Incorporation of immunotherapy for high-risk locally advanced disease
Pembrolizumab added to concurrent chemoradiotherapy improved overall survival in KEYNOTE-A18, with continued pembrolizumab monotherapy after the chemoradiation phase [2].
Key Evidence Supporting Combination Chemo-RT and Immunotherapy
In KEYNOTE-A18 (ENGOT-cx11/GOG-3047), pembrolizumab plus chemoradiotherapy improved survival outcomes versus chemoradiotherapy alone in previously untreated high-risk locally advanced cervical cancer [2]. Published summaries of KEYNOTE-A18 describe clinically meaningful progression-free and overall survival benefits with a manageable toxicity profile, supporting integration of this approach for high-risk patients in guideline-concordant practice ASCO Post (2024).
Target Blood Pressure, Treatment Goals, and Follow-up Scope
The therapeutic goal in curative-intent settings is durable local control with reduction in recurrence risk using stage-appropriate definitive therapy, combining local radiation strategies with systemic therapy for radiosensitization when indicated ESMO 2023 Gynaecological Cancers. Follow-up strategy is risk-adapted and should include surveillance for recurrence and management of treatment-related sequelae consistent with invasive cervical cancer care pathways [3].